SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Pavani Chalasani, MD, MPH
Erica L. Mayer, MD, MPH
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Jacob Sands, MD
Aaron Lisberg, MD
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Julia Rotow, MD
Xiuning Le, MD, PhD
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Alexandria May, PharmD, BCPS
Daniel Landi, MD
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Casey Cosgrove, MD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Victoria Coleman-Cowger, PhD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.